ALNYLAM PHARMACEUTICALS, INC. OCI, before Reclassifications, Net of Tax, Attributable to Parent
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported OCI, before Reclassifications, Net of Tax, Attributable to Parent of -$10.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2025-12-31 was $1.74M.
- ALNYLAM PHARMACEUTICALS, INC. oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2025-09-30 was $8.41M, a 1096.87% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2025-06-30 was $7.91M.
- ALNYLAM PHARMACEUTICALS, INC. oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2025-03-31 was -$2.56M.
- ALNYLAM PHARMACEUTICALS, INC. oci, before reclassifications, net of tax, attributable to parent for fiscal 2025 was $15.51M.
- ALNYLAM PHARMACEUTICALS, INC. oci, before reclassifications, net of tax, attributable to parent for fiscal 2024 was -$11.25M, a 194.44% decline from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. oci, before reclassifications, net of tax, attributable to parent for fiscal 2023 was $11.92M.
- ALNYLAM PHARMACEUTICALS, INC. oci, before reclassifications, net of tax, attributable to parent for fiscal 2022 was -$5.26M.
| Period end | OCI, before Reclassifications, Net of Tax, Attributable to Parent 3 month | OCI, before Reclassifications, Net of Tax, Attributable to Parent 6 month | OCI, before Reclassifications, Net of Tax, Attributable to Parent 9 month | OCI, before Reclassifications, Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$10.20M 10-Q · filed 2026-07-30 | |||
| 2025-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $10.16M derived: sum of 2 quarters · filed 2026-02-12 | $18.06M derived: sum of 3 quarters · filed 2026-07-30 | $15.51M 10-K · filed 2026-02-12 |
| 2025-09-30 | $8.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $16.32M derived: sum of 2 quarters · filed 2026-07-30 | $13.77M 10-Q · filed 2025-10-30 | $8.84M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $7.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $5.35M 10-Q · filed 2026-07-30 | $429.00K derived: sum of 3 quarters · filed 2026-07-30 | $1.13M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$2.56M 10-Q · filed 2025-05-01 | -$7.48M derived: sum of 2 quarters · filed 2026-02-12 | -$6.78M derived: sum of 3 quarters · filed 2026-02-12 | -$13.72M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-12-31 | -$4.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | -$4.22M derived: sum of 2 quarters · filed 2026-02-12 | -$11.17M derived: sum of 3 quarters · filed 2026-02-12 | -$11.25M 10-K · filed 2026-02-12 |
| 2024-09-30 | $703.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$6.25M derived: sum of 2 quarters · filed 2025-10-30 | -$6.33M 10-Q · filed 2025-10-30 | -$2.76M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | -$6.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | -$7.03M 10-Q · filed 2025-07-31 | -$3.46M derived: sum of 3 quarters · filed 2025-07-31 | -$590.00K derived: sum of 4 quarters · filed 2025-07-31 |
| 2024-03-31 | -$84.00K 10-Q · filed 2025-05-01 | $3.49M derived: sum of 2 quarters · filed 2025-05-01 | $6.36M derived: sum of 3 quarters · filed 2025-05-01 | $10.43M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $3.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $6.44M derived: sum of 2 quarters · filed 2025-02-13 | $10.52M derived: sum of 3 quarters · filed 2025-02-13 | $11.92M 10-K · filed 2025-02-13 |
| 2023-09-30 | $2.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $6.95M derived: sum of 2 quarters · filed 2024-10-31 | $8.35M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $4.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $5.47M 10-Q · filed 2024-08-01 | ||
| 2023-03-31 | $1.40M 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | -$5.26M 10-K · filed 2024-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |